Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study

Background: we have observed the effect of insomnia treatment in clinical and prognostic differences of patients admitted for COVID-19 pneumonia in respiratory sub-intensive units that were administered a prolonged-release melatonin 2 mg (PRM 2 mg) therapy versus a group of patients out of therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Bologna, Carolina, Madonna, Pasquale, Pone, Eduardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705392/
https://www.ncbi.nlm.nih.gov/pubmed/34945156
http://dx.doi.org/10.3390/jcm10245857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705392/
https://www.ncbi.nlm.nih.gov/pubmed/34945156
http://dx.doi.org/10.3390/jcm10245857

Ejemplares similares